Status Epilepticus Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Conclusive and Non-Conclusive Epilepticus), By Drug (Ganaxolone, Diazepam, Phenobarbital, Phenytoin and Fosphenytoin, Valproate, and Others), By Distribution Channel (Retail Pharmacy, Online Pharmacy, and Hospital Pharmacy), and Region

Status Epilepticus Market size was valued at US$ 1,316 million in 2023 and is expected to reach US$ 2,178 million by 2030, growing at a 6.5% CAGR from 2024 to 2030. According to the National Institutes of Health, Status epilepticus is defined as a seizure with 5 minutes or more of continuous clinical and/or electrographic seizure activity or recurrent seizure activity without recovery between seizures. Status epilepticus treatment is addressed rapidly and in an organized manner with simultaneous management of the breathing, circulation, and airway while administering antiepileptic drug treatment.

The primary objective is to abort the seizure as rapidly as possible with no harm to the patient to their cardiovascular systems. Drugs included for treatment are ganaxolone, diazepam, phenobarbital, phenytoin Fosphenytoin, and others. The high prevalence of the neurological disorder among men is expected to increase in demand, the epidemiology of epilepticus shows a higher risk of epilepsy in men as compared to women.

According to the World Health Organization (WHO), Status epilepticus is a chronic, noncommunicable disease that affects more than 55 million people across the world. With the increasing prevalence of neurological disorders government is providing funding for research and development activities, enhancing clinical trials for such drugs, and raising drug approval by authorized organizations to lower the risk for epilepsy disorder in the market which leads to creating new opportunities in the market. With the amplified cost of expenditure for the treatment several key players spend a lot in research and development for the treatment, and in return the cost has increased, a greater number of economic people are unable to proceed due to high treatment costs which are the major restraints. 

Market Key Developments

In March 2022, Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder. ZTALMY® (ganaxolone) is an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD), a rare form of genetic epilepsy, in patients two years of age and older, ZTALMY® is a neuroactive steroid that acts as a positive allosteric modulator of the GABAA receptor.